Promotion of murine antitumor activity by prothymosin alpha treatment: I. Induction of tumoricidal peritoneal cells producing high levels of tumour necrosis factor alpha
- PMID: 1596938
- PMCID: PMC11038346
- DOI: 10.1007/BF01741862
Promotion of murine antitumor activity by prothymosin alpha treatment: I. Induction of tumoricidal peritoneal cells producing high levels of tumour necrosis factor alpha
Abstract
The effect of prothymosin alpha (ProT alpha) on the survival of DBA/2 mice inoculated with syngeneic tumour cells was studied. DBA/2 mice inoculated intraperitoneally (i.p.) with 2 x 10(5) syngeneic leukaemic L1210 cells developed ascites within 8-12 days and died 10-14 days later. Treatment with ProT alpha consistently inhibited the development of ascites in 20% of the treated animals and prolonged the survival of 40%-60% of the animals up to 70 days. The most effective treatment schedule of ProT alpha was 300 ng/mouse given i.p. at 2-day intervals for 3 weeks followed by a rest period of 7 days, prior to tumour cell inoculation. Peritoneal exudate (PE) cells collected from mice treated with the optimal dose of ProT alpha produced, in the absence of exogenous stimulus, six- to eightfold higher levels of tumour necrosis factor alpha (TNF alpha) than PE cells from control mice. Furthermore these cells exhibited cytotoxic activity against several tumour cell lines including the syngeneic L1210, the TNF-insensitive P815 mastocytoma, the human MOLT-4 lymphoblastic leukaemia, as well as the murine TNF-sensitive L929 fibroblast cell line. Kinetic studies revealed that both production of TNF alpha and tumoricidal activity peaked 7 days after the last injection of ProT alpha and were maintained at high levels over a period of 1 month. Injections with 150 ng ProT alpha slightly improved the survival of mice whereas higher (500 ng and 1000 ng) doses of ProT alpha and a wide range of thymosin alpha 1 doses remained without any effect. PE cells collected from these mice produced extremely low levels of TNF alpha and exhibited negligible tumoricidal activity. Our data demonstrate that ProT alpha has a protective effect in vivo against the growth of adoptively transferred tumour cells and suggest that this effect is, at least in part, mediated by ProT alpha-activated PE cells. These cells were demonstrated to produce high levels of TNF alpha in vitro and to exhibit activity against both TNF-sensitive and TNF-resistant cell lines.
Similar articles
-
Induction of tumor-specific T lymphocyte responses in vivo by prothymosin alpha.Cancer Immunol Immunother. 1995 Jun;40(6):410-8. doi: 10.1007/BF01525392. Cancer Immunol Immunother. 1995. PMID: 7543022 Free PMC article.
-
Induction of lymphokine-activated killer activity in mice by prothymosin alpha.Cancer Immunol Immunother. 1994 Apr;38(4):281-6. doi: 10.1007/BF01533521. Cancer Immunol Immunother. 1994. PMID: 8168124 Free PMC article.
-
Prothymosin alpha 1 effects, in vitro, on the antitumor activity and cytokine production of blood monocytes from colorectal tumor patients.Int J Immunopharmacol. 1997 Jun;19(6):323-32. doi: 10.1016/s0192-0561(97)00024-6. Int J Immunopharmacol. 1997. PMID: 9467751
-
Prothymosin alpha.Int J Biochem Cell Biol. 1999 Nov;31(11):1243-8. doi: 10.1016/s1357-2725(99)00094-1. Int J Biochem Cell Biol. 1999. PMID: 10605816 Review.
-
Tumour necrosis factor-alpha as a tumour promoter.Eur J Cancer. 2006 Apr;42(6):745-50. doi: 10.1016/j.ejca.2006.01.012. Epub 2006 Mar 6. Eur J Cancer. 2006. PMID: 16517151 Review.
Cited by
-
Prothymosin Alpha and Immune Responses: Are We Close to Potential Clinical Applications?Vitam Horm. 2016;102:179-207. doi: 10.1016/bs.vh.2016.04.008. Epub 2016 May 27. Vitam Horm. 2016. PMID: 27450735 Free PMC article. Review.
-
Interleukin-2-activated killer cell activity in colorectal tumor patients: evaluation of in vitro effects by prothymosin alpha1.J Cancer Res Clin Oncol. 1997;123(8):420-8. doi: 10.1007/BF01372545. J Cancer Res Clin Oncol. 1997. PMID: 9292704 Free PMC article.
-
Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide.Cancers (Basel). 2019 Nov 9;11(11):1764. doi: 10.3390/cancers11111764. Cancers (Basel). 2019. PMID: 31717548 Free PMC article.
-
Induction of tumor-specific T lymphocyte responses in vivo by prothymosin alpha.Cancer Immunol Immunother. 1995 Jun;40(6):410-8. doi: 10.1007/BF01525392. Cancer Immunol Immunother. 1995. PMID: 7543022 Free PMC article.
-
Boosting immune response to hepatitis B DNA vaccine by coadministration of Prothymosin alpha-expressing plasmid.Clin Diagn Lab Immunol. 2005 Dec;12(12):1364-9. doi: 10.1128/CDLI.12.12.1364-1369.2005. Clin Diagn Lab Immunol. 2005. PMID: 16339058 Free PMC article.
References
-
- Asher A, Mule JJ, Reicher CM, Shiloni E, Rosenberg SA. Studies on the anti-tumour efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol. 1987;130:963. - PubMed
-
- Baxevanis CN, Reclos GJ, Papamichail M. Decreased HLA-DR antigen expression on monocytes causes impaired suppressor cell activity in multiple sclerosis. J Immunol. 1970;144:4166. - PubMed
-
- Baxevanis CN, Reclos GJ, Papamichail M, Tsokos GC. Prothymosin α restores the depressed autologous and allogeneic mixed lymphocyte reaction in patients with systemic lupus erythematosus. Immunopharmacol Immunotoxicol. 1987;9:429. - PubMed
-
- Baxevanis CN, Reclos GJ, Sfagos C, Matikas N, Papamichail M. In: Trends in European multiple sclerosis research: effects of prothymosin α on the defective autologous mixed lymphocyte reaction in patients with multiple sclerosis. Confavreoux C, Aimard G, Devic M, editors. Amsterdam: Elsevier; 1987. p. 58.
-
- Baxevanis CN, Reclos GJ, Economou M, Arsenis P, Katsiyiannis A, Seferiades K, Papadopoulos G, Tsoloas O, Papamichail M. Mechanism of action of prothymosin α in the human autologous mixed lymphocyte response. Immunopharmacol Immunotoxicol. 1988;10:443. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources